This Webcast will discuss the use of pharmacologic strategies subsequent to ACS and PCI. Landmark trials that established how contemporary antiplatelet strategies are applied in this setting will be discussed in the context of the risk of suboptimal platelet inhibition. Best practices for transitioning patients from inpatient to outpatient care will be addressed, with a focus on adherence to guideline-recommended strategies.

This educational activity will review the etiology of bacterial conjunctivitis, describe the symptoms and factors to consider when establishing the clinical diagnosis, discuss the effect of topical antibiotics on the disease course, and outline key points to communicate to patients and/or caregivers to optimize medical therapy.

In this online presentation, participants will learn about the most current criteria for MS diagnosis and new developments to be used in diagnostic imaging, prognostic indicators for current therapies, findings from long-term clinical trials, as well as the benefits and risks of new and emerging therapies.

This educational activity will review how to screen patients prone to inflammation-related complications post-cataract surgery, review the local ocular approaches to controlling cataract surgery-related inflammation, describe the local ocular approaches to controlling the inflammation of noninfectious uveitis, and discuss how to educate patients about the proper use of topical ophthalmic and anti-inflammatory agents.

This eTutorial Webcast will assess current and emerging methods that apply immune-based strategies to the treatment of castration-resistant prostate cancer. During this program, traditional management strategies for castration-resistant prostate cancer will be reviewed. The basic science that underlies the development of immunological strategies for prostate cancer will be explored, as well as clinical trials that have assessed these approaches in patients with these tumors.

This Expert Commentary will review how to integrate personalized targeted therapy into the treatment of patients with HCC, manage toxicities of anti-cancer agents used in HCC, learn and apply the different staging and scoring systems used in HCC, and how to develop a strategy to enhance the multi-disciplinary approach for the management of HCC.

This CME initiative is designed to educate healthcare providers involved in the management of patients with RA. The goal of this activity is to present the most practical and beneficial information on assessment, intervention, and cohesive, individualized management strategies. The educational format of "Rheumatoid Arthritis 2011" consists of problem-based learning for clinical decision making. This 1 hour CME webcast will be hosted by CME University, freeCME.com, and Powerpak.com. Level 3 and 4 outcomes measurements will be obtained utilizing pre- and post-test surveys to gauge changes in knowledge and competency. Level 5 performance changes will be assessed using follow-up case vignettes issued 4-6 weeks following the activity.

As the second leading cause of cancer deaths, colorectal cancer (CRC) remains a major health problem in the United States. Although up to 90% of these tumors are curable if treated at early stages, a significant number of patients are not diagnosed with CRC until it has metastasized. Clearly, the need for improved screening and early detection is critical. Additionally, there continues to be a need for improved strategies to manage patients with metastatic disease. In recent years, advances in our understanding of tumor biology have resulted in the development of targeted therapies and increased attention to the role of molecular markers. This has allowed practitioners to employ more individualized approaches in their treatment of patients with advanced CRC. This program will review the use of molecular markers, evaluate the treatment options available, and summarize the management of the most common treatment-related adverse events to advance the knowledge of health care providers caring for patients with metastatic colorectal cancer.

Physicians and health care professionals believe that urinary incontinence is an expected outcome of aging. As a patient transitions from middle age through to old age, the consequences of incontinence move from toilet mapping and quality of life to isolation, depression, and increased risk of falls. Physicians must juggle co-morbidities in the older patient and identify appropriate behavioral and pharmacotherapy to meet the patient's needs and expectations.

This case-based interactive program will summarize the current evidence in support of HER2 testing and the interpretation of currently used testing methods, review clinical trials that have assessed HER2-targeted strategies in adjuvant and metastatic treatment settings in patients with breast cancer, apply pivotal clinical trial results to the management of patients with HER2-positive breast cancer, and describe how health care provider/patient communication techniques can be integrated into the routine care of patients with breast cancer.

This Simulated Live Broadcast is a 1-hour presentation, led by 2 faculty speakers and 1 moderator, that incorporates didactic lectures with case-based presentations. At the conclusion of the first week of the broadcast, the initial broadcast participants will have the opportunity to submit a moderated question to the faculty via teleconference line.

This webcast which is based on the content of a case-based satellite symposium that took place at AUA will assess current and emerging immune-based methods to manage castration-resistant prostate cancer. During this program, immunological mechanisms that have been investigated for their utility in the setting of prostate cancer will be explored. Clinical trial results will be discussed and assessed in the context of their impact on state-of-the-art care to manage these difficult-to-treat forms of prostate cancer.

The Validation Model^SM is a new four-part series that seeks to enhance communication between patients and their health care providers. Patients with hepatitis C virus (HCV) infection will be surveyed twice throughout the series to obtain a better understanding of their perspective about their disease and treatment experience. This important survey information will enable health care professionals to address their patients’ greatest concerns about their disease and ultimately lead to improved patient care. The Patient or KNOW Patient^™ is the third part in the series.

Bringing Outcomes Into Focus: A Learner's Guide to Translating Theory Into Action

The Reflective Case-Study Outcomes Compendium will review the results of the aforementioned patient surveys, summarize the key concepts of other activities, and provide a detailed overview of the educational outcomes as measured by pre- and post-test data. This information creates the opportunity to assess where you stand against your peers in the aggregate and where this medical oncology specialty community sits as a whole.

This program will review current imaging techniques for diagnosing MS and monitoring patient response to therapy, as well as clinical trial data on current and emerging treatments. Additionally, the impact of MS on quality of life and steps that can be taken to improve quality of life for these patients will be addressed.

Enhancing Osteoporosis Management Using a Performance Improvement Approach is an integrated educational Performance Improvement activity which will allow all participants to access a variety of learning formats and tools to assess and improve those involved in the care of patients who are diagnosed with or are at risk for developing osteoporosis.

Primary Cares: A Performance Improvement Activity Designed to Improve the Diagnosis and Management of COPD and Asthma is an integrated educational Performance Improvement activity which will allow all participants to access a variety of learning formats and tools to assess and improve those involved in the care of patients who are diagnosed with asthma or chronic obstructive pulmonary disease (COPD).

This educational activity will provide the attendee with an overview of the current clinical trial data on NSCLC while highlighting diagnostic tools, current first- and second-line approaches to manage advanced disease, and developments in maintenance therapy. Finally, strategies to individualize therapy will be reviewed.

Breast cancer represents a heterogeneous array of different disease subtypes that have unique molecular phenotypes and distinct clinical features. Despite advances in the treatment of early-stage breast cancer, approximately one third of patients will eventually develop metastatic breast cancer (MBC). The increased understanding of the biology of breast cancer has led to the classification of tumors based upon their molecular features and the development and use of targeted therapies for the treatment of both early and metastatic cancer. Targeted agents and their promise of better patient outcomes with respect to safety, survival, and quality of life may change the clinical course for many MBC patients.